Results based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

HeartMate 3 LVAD Provides Immediate, Significant and Sustained Improvements in Functional Capacity and Quality of Life

Significant Increase in 6-Minute Walk Distance

At baseline, tested patients completed the 6-minute walk test at an average of 136 meters. At 2 years after HeartMate 3™ LVAD implant, patients completed the test at an average of 323 meters.¹

MOMENTUM 3 Trial

This device is commercially available for use in select international markets.

*Based on HeartMate 3 LVAD highest published survival and lowest published stroke and thrombosis rates in a randomized controlled trial for continuous-flow LVAD category of devices in the U.S.^1-3,5
†HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
^§For a continuous-flow LVAD in a randomized controlled trial.
^‡INTERMACS: International Registry for Mechanically Assisted Circulatory Support.
^#Key adverse events include pump thrombosis, stroke and gastrointestinal bleeding.

References

1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
2. Rogers JG, Pagani F, Tatooles A, et al. Intrapericardial left ventricular assist device for advanced heart failure. New Engl J Med. 2017;376:451-460.
3. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
4. Teuteberg JJ, Cleveland JC, Cowger J, Higgins RS, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: the changing landscape of devices and indications. Ann Thorac Surg. 2020;109:649-660.
5. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting; April 4, 2019; Orlando, FL.
6. Mehra MR. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report for the MOMENTUM 3 Trial. American College of Cardiology (ACC) Annual Meeting; March 17, 2019; New Orleans, LA.